Why DANYELZA® (naxitamab-gqgk)?

Why DANYELZA?

1

DANYELZA® is FDA approved specifically for relapsed or refractory high-risk neuroblastoma in the bone or bone marrow in patients who have shown a partial response, minor response, or stable disease to prior therapy

Nobody wants to hear that their child’s high-risk neuroblastoma has returned or has been unresponsive to treatment. Fortunately, research has led to an additional treatment option called DANYELZA, which is used in combination with a medicine called granulocyte-macrophage colony-stimulating factor (GM-CSF).

The chart below helps explain when DANYELZA can be used*

DANYELZA Treatment Options Chart DANYELZA Treatment Options Chart
DANYELZA Caregiver, Spencer

"There were moments where we had helplessness or hopelessness, but then there was the moment when we heard about this treatment and knew that it was available for Ava."

–Spencer, actual DANYELZA caregiver

Get help finding your child’s path forward

This personalized guide can help you have a conversation with your child’s HCP to determine if DANYELZA could be an appropriate treatment option for your child.

Get started >

Provided the patient has disease in the bone and/or bone marrow.

2

DANYELZA is a humanized immunotherapy

DANYELZA Antibody Icon

This means it is made to more closely resemble antibodies that are already in the body

DANYELZA is used in combination with GM-CSF, a medicine that helps the immune system during treatment.

Learn more about the safety and side effects of DANYELZA >

Research suggests that DANYELZA fights high-risk neuroblastoma by helping your child’s immune system recognize and destroy the cancer cells*

  • It does this by attaching to markers called GD2, which are found on the surface of neuroblastoma cells
  • The immune system recognizes DANYELZA once it is attached and kills the cancer cells
  • Other cells in the body, such as nerve cells, pain fibers, and certain skin cells, also have GD2 on their surface
  • Because of this, DANYELZA can cause side effects such as pain (which may be severe) when it attaches to those cells
  • There are recommendations for managing these side effects before and during DANYELZA treatment. Your child’s care team will follow these throughout the process
  • See recommendations >

How DANYELZA works in the body

DANYELZA Attaching to GD2 and Attacking Cancer Cells

DANYELZA attaches to the
GD2 on the cancer cell

DANYELZA Attaching to GD2 on the Cancer Cell

This sends a signal to the immune system
telling it to attack the cancer cell

DANYELZA Signaling to the Immune System to Attack Cancer Cells

The body’s immune
cells kill the cancer cell

Based on studies not conducted in humans.

3

DANYELZA was studied in an outpatient setting

DANYELZA infusions will last between 30 and 60 minutes, with the first infusion (Cycle 1, Day 1) being over 60 minutes, as tolerated

Your child’s doctor will determine if infusions in an outpatient setting may be an option.

Your child will be closely monitored by their care team for side effects throughout treatment, as well as for some time after the infusion is complete. This will happen whether they receive DANYELZA in an inpatient or an outpatient setting.

See the treatment schedule >

DANYELZA Caregiver, Rachalle

"So in speaking with our child’s doctor, we had the option to have outpatient treatment, which was huge for Luke. Having the opportunity to leave the hospital setting where we can make it more like home and more kid-friendly, that's definitely something that we want for him."

–Rachalle, caregiver ambassador

Quick links

Visit the glossary to better
understand the science

How to talk to your doctor
about getting DANYELZA

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about DANYELZA?
DANYELZA may cause serious side effects, including:

Serious infusion-related reactions. DANYELZA can cause serious infusion-related reactions that require immediate medical attention. Infusion-related reactions are common with DANYELZA. Tell your healthcare provider right away if you get any signs or symptoms during or after your DANYELZA infusion, including:

  • swelling of your face, eyes, lips, mouth, or tongue
  • itching
  • redness on your face (flushing)
  • skin rash or hives
  • trouble breathing
  • cough or wheezing
  • noisy high-pitched breathing
  • feeling faint or dizziness (low blood pressure)

WHAT IS DANYELZA?

DANYELZA is a prescription medicine used in combination with a medicine called granulocyte-macrophage colony-stimulating factor (GM-CSF) to treat children 1-year of age and older and adults with high-risk neuroblastoma in the bone or bone marrow that:

  • has come back (relapsed) or that did not respond to previous treatment (refractory), and
  • has shown a partial response, minor response, or stable disease to prior therapy.

DANYELZA is approved based on two clinical studies that looked at reducing tumor size. DANYELZA is still being studied to confirm the study results and the clinical benefit of treatment.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about DANYELZA?
DANYELZA may cause serious side effects, including:

Serious infusion-related reactions. DANYELZA can cause serious infusion-related reactions that require immediate medical attention. Infusion-related reactions are common with DANYELZA. Tell your healthcare provider right away if you get any signs or symptoms during or after your DANYELZA infusion, including:

  • swelling of your face, eyes, lips, mouth, or tongue
  • itching
  • redness on your face (flushing)
  • skin rash or hives
  • trouble breathing
  • cough or wheezing
  • noisy high-pitched breathing
  • feeling faint or dizziness (low blood pressure)

WHAT IS DANYELZA?

DANYELZA is a prescription medicine used in combination with a medicine called granulocyte-macrophage colony-stimulating factor (GM-CSF) to treat children 1-year of age and older and adults with high-risk neuroblastoma in the bone or bone marrow that:

  • has come back (relapsed) or that did not respond to previous treatment (refractory), and
  • has shown a partial response, minor response, or stable disease to prior therapy.

DANYELZA is approved based on two clinical studies that looked at reducing tumor size. DANYELZA is still being studied to confirm the study results and the clinical benefit of treatment.

Nervous system problems. Talk to your healthcare provider right away if you have new symptoms or worsening of nervous system problems, including:

  • Severe pain from nerves (neuropathic pain), including pain in the belly (abdomen), bone, neck, legs, or arms. Pain is common with DANYELZA and can be severe.
  • Inflammation of the spinal cord. Signs or symptoms may include:
    • weakness in your legs or arms
    • bladder and bowel problems
    • pain in back, legs, or stomach (abdomen)
    • numbness
    • tingling
    • burning sensation
  • Reversible Posterior Leukoencephalopathy Syndrome (RPLS – also known as Posterior Reversible Encephalopathy Syndrome - PRES). PRES is a condition that affects the brain. Your healthcare provider will monitor your blood pressure and check for any neurologic symptoms after your DANYELZA infusion. Signs or symptoms of PRES may include:
    • severe headache
    • vision changes
    • changes in mental status, such as confusion, disorientation, or decreased alertness
    • difficulty speaking
    • weakness in your arms or legs
    • seizures
  • Numbness, tingling, or burning sensation in the arms or legs.
  • Nervous system problems of the eye. Signs or symptoms may include:
    • unequal pupil size
    • blurred vision
    • trouble focusing your eyes
    • larger pupil size (dilated)
    • decreased ability to see
    • sensitivity to light
  • Problems urinating or emptying your bladder (prolonged urinary retention).

Do not receive DANYELZA if you have had a severe allergic reaction to naxitamab-gqgk (the active ingredient in DANYELZA). Ask your healthcare provider if you are not sure.

Before receiving DANYELZA, tell your healthcare provider about all your medical conditions, including if you:

  • have high blood pressure
  • are pregnant or plan to become pregnant. DANYELZA may harm your unborn baby.
    • Your healthcare provider will do a pregnancy test before you start treatment with DANYELZA.
    • Females who are able to become pregnant should use effective birth control (contraception) during treatment and for 2 months after your last dose of DANYELZA. Talk to your healthcare provider about birth control choices that may be right for you during this time.
    • Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with DANYELZA.
  • are breastfeeding or plan to breastfeed. It is not known if DANYELZA passes into your breast milk. Do not breastfeed during treatment and for 2 months after your last dose of DANYELZA.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of DANYELZA?
DANYELZA may cause serious side effects, including:

  • See “What is the most important information I should know about DANYELZA?”
  • High blood pressure (hypertension). High blood pressure is common in people who receive DANYELZA. Your blood pressure will be monitored during your DANYELZA infusion, and at least each day on Days 1 to 8 of each DANYELZA treatment cycle. Tell your healthcare provider right away if you get any signs or symptoms of high blood pressure, including:
    • headaches
    • seizures
    • nausea or vomiting
    • chest pain
    • dizziness
    • visual changes
    • shortness of breath
    • feeling that your heart is pounding or racing (palpitations)
    • nose bleeds

The most common side effects of DANYELZA include:

  • fast heart rate
  • vomiting
  • cough
  • nausea
  • decreased white blood cell, red blood cell, and platelet counts
  • diarrhea
  • decreased appetite
  • tiredness
  • skin rashes
  • decreased level of potassium, sodium, and phosphate in the blood
  • hives
  • fever
  • headache
  • injection site reaction
  • swelling of the body or only in one part of the body
  • anxiety
  • irritability
  • increased liver function blood tests
  • decreased blood sugar level
  • decreased calcium levels in the blood
  • decreased protein levels (albumin) in the blood

These are not all of the possible side effects of DANYELZA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please click for full Prescribing Information and Patient Information for DANYELZA including Boxed Warning on serious infusion-related reactions and nervous system problems, and talk to your doctor.